Clinical Trial Update: Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating oral Bevacizumab-800CW and Cetuximab-800CW as imaging agents to detect early esophageal adenocarcinomas in individuals with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Barrett Esophagus Without Dysplasia
• Barrett Esophagus with Dysplasia
• Esophageal Adenocarcinoma

Drugs mentioned

• Bevacizumab-800CW (bevacizumab-800CW)
• Cetuximab-800CW (cetuximab-800CW)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Barrett's Esophagus Without Dysplasia, Barrett Oesophagitis With Dysplasia | Phase 2 | Status: RECRUITING